Bristol-Myers SquibbBMY
BMY
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
220% more first-time investments, than exits
New positions opened: 342 | Existing positions closed: 107
50% more funds holding in top 10
Funds holding in top 10: 26 [Q3] → 39 (+13) [Q4]
11% more capital invested
Capital invested by funds: $82B [Q3] → $91.4B (+$9.4B) [Q4]
8% more funds holding
Funds holding: 2,224 [Q3] → 2,413 (+189) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 906 | Existing positions reduced: 901
0% more call options, than puts
Call options by funds: $1.75B | Put options by funds: $1.75B
0.13% more ownership
Funds ownership: 78.25% [Q3] → 78.39% (+0.13%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
8%
downside
Avg. target
$62
3%
upside
High target
$65
8%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
Wells Fargo Mohit Bansal 44% 1-year accuracy 12 / 27 met price target | 3%upside $62 | Equal-Weight Maintained | 7 Feb 2025 |
Cantor Fitzgerald Olivia Brayer 68% 1-year accuracy 13 / 19 met price target | 8%downside $55 | Neutral Maintained | 4 Feb 2025 |
Citigroup Andrew Baum 50% 1-year accuracy 3 / 6 met price target | 8%upside $65 | Neutral Maintained | 28 Jan 2025 |
Truist Securities Robyn Karnauskas 27% 1-year accuracy 3 / 11 met price target | 8%upside $65 | Buy Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 42 articles about BMY published over the past 30 days
Positive
Seeking Alpha
14 hours ago
Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)
We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable income strategy for Options. This monthly series provides two lists of stocks suitable for writing options to generate relatively safe income, focusing on PUT and CALL options.
Neutral
CNBC Television
2 days ago
Final Trade: DIS, BMY, AMZN, XMAG
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Neutral
Business Wire
2 days ago
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo.
Neutral
Business Wire
2 days ago
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications.
Negative
Market Watch
3 days ago
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector.
Positive
The Motley Fool
3 days ago
3 Deeply Discounted Dividend Stocks to Buy Today
Want to buy a good dividend stock and secure a great price in the process? I have a list of three stocks that can help you diversify your portfolio, allow you to earn above-average dividends, and score some potential bargains in the process.
Neutral
Zacks Investment Research
4 days ago
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.
Neutral
Seeking Alpha
5 days ago
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to value/ defensive stocks. This is significantly aided by the double beat FQ4'24 performance and the decent FY2025 guidance, as the management drives renewed growth through new portfolios and M&A activities. Despite the higher net debts on balance sheet, we believe that BMY's dividends remain safe as observed in the richer cash flows and recent payout raise.
Positive
Investors Business Daily
6 days ago
Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend Yield
The sold call produces a 9.83% annualized yield in addition to the dividend. The post Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend Yield appeared first on Investor's Business Daily.
Positive
Benzinga
6 days ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Charts implemented using Lightweight Charts™